CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 56 enrolled
Drug / intervention
Mepivacaine +1 moredrug
Likely dose
Mepivacaine 1.8 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02110966
NCT02110966Phase 4Completed
CompareCT.gov

Efficacy of the Combination Mepivacaine-Tramadol on the Success of Inferior Alveolar Nerve Block in Patients With Symptomatic Irreversible Pulpitis: a Randomized Clinical Trial.

Daniel Chavarría Bolaños·interventional·Posted Apr 10, 2014·Updated Oct 31, 2014

In Brief

A Phase 4 clinical trial evaluating Mepivacaine and Mepivacaine plus Tramadol for Symptomatic Irreversible Pulpitis. Completed, enrolled 56 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the success of inferior alveolar nerve block, after the local application of Mepivacaine plus Tramadol in patients with symptomatic irreversible pulpitis. Also, to evaluate the duration of the anesthetic effect when using Mepivacaine plus Tramadol in the same anesthetic technique and patients group. Hypothesis: Local application of mepivacaine plus tramadol increases the successful of inferior alveolar nerve block in patients with irreversible pulpitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSymptomatic Irreversible Pulpitis
CountriesMexico
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 10, 2014
Enrollment StartApr 1, 2014
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 12.2 years ago

Interventions

Mepivacainedrug

Drug: Tramadol 1.8 ml of Mepivacaine 2% epinephrine 1:100000.

Mepivacaine plus Tramadoldrug

0.5 ml of Tramadol mixed with 1.3 ml of Mepivacaine.